Candriam SCA’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Candriam SCA’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-57,201	Closed	-$18.1M	–	747
2023 Q4	$18.1M	Sell	57,201 -4,000	-7%	-$778K	0.13%	170
2023 Q3	$10.3M	Sell	61,201 -6,000	-9%	-$1.13M	0.07%	228
2023 Q2	$14.6M	Hold	67,201	–	–	0.11%	198
2023 Q1	$11.2M	Sell	67,201 -15,000	-18%	-$2.87M	0.08%	242
2022 Q4	$16.2M	Hold	82,201	–	–	0.11%	193
2022 Q3	$18.5M	Sell	82,201 -6,526	-7%	-$1.32M	0.13%	174
2022 Q2	$11.2M	Buy	88,727 +26,632	+43%	+$3.06M	0.09%	210
2022 Q1	$7.87M	Buy	62,095 +43,039	+226%	+$4.85M	0.05%	288
2021 Q4	$2.5M	Sell	19,056 -35,694	-65%	-$4.61M	0.02%	502
2021 Q3	$6.7M	Hold	54,750	–	–	0.05%	336
2021 Q2	$6.24M	Buy	+54,750	New	+$6.4M	0.04%	364

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Candriam SCA's KRTX Position: Q1 2024 in Review

Candriam SCA sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 57,201 shares — an estimated $18.1M sold.

Candriam SCA first reported a position in KRTX in Q2 2021 and held it in 11 quarters. The position peaked at $18.5M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Candriam SCA reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Candriam SCA sold 57,201 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $18.1M.
Candriam SCA first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
Candriam SCA's Karuna Therapeutics, Inc. Common Stock position peaked at $18.5M in Q3 2022.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.